Oramed to start oral insulin trial in Israel

By Elaine Rigoli

Tampa, Fla., July 11 - Oramed Pharmaceuticals, Inc. said the Israeli Ministry of Health has given final approval allowing the phase 1 clinical study of oral insulin in healthy volunteers.

Preceding the approval, Hadassah Medical Center IRB (Institutional Review Board) also gave its approval to Oramed's application for phase 1 clinical trials of oral insulin in healthy humans.

Hadassah's IRB, designed primarily to protect study participants, is made up of a group of scientists, doctors, clergy and consumers at each health care facility that participates in a clinical trial.

The Ministry of Health is responsible for supervising, monitoring and regulating the pharmaceuticals sector, by licensing medicinal preparations and setting standards for medicinal and cosmetic preparations, as well as for toxic substances, among many other services for the public.

Oramed, based in Jerusalem, Israel, is a company focused on the development of oral delivery solutions based on proprietary technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.